GO:0016937 short-chain fatty acyl-CoA dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016937 describes the enzymatic activity that removes two hydrogens from a short-chain (fewer than 6 carbons) fatty acyl-CoA, producing a 2,3-unsaturated enoyl-CoA and transferring electrons to electron-transfer flavoprotein.
• The reaction is the first step of mitochondrial fatty acid beta-oxidation for short-chain substrates and is catalyzed by short-chain acyl-CoA dehydrogenase (SCAD, gene ACADS).
• SCAD deficiency alters lipid handling and has been linked to metabolic phenotypes such as protection against diet-induced obesity and insulin resistance in mouse models.
• SCAD expression and activity change during cardiac development and under stress, and modulate cardiomyocyte apoptosis.
• SCAD is a potential therapeutic target in vascular remodelling, connecting this enzymatic activity to smooth-muscle and endothelial biology.
• Research on GO:0016937 uses enzyme activity assays, native electrophoresis in-gel activity assays, metabolic flux measurements, and CRISPR-engineered cell and animal models.
Description
GO:0016937, short-chain fatty acyl-CoA dehydrogenase activity, is a molecular function that catalyzes the oxidation of a short-chain 2,3-saturated fatty acyl-CoA to a short-chain (2E)-enoyl-CoA, with concomitant reduction of electron-transfer flavoprotein. Short-chain fatty acids are defined as having an aliphatic tail of fewer than six carbons, so this activity acts on substrates such as butanoyl-CoA and related acyl-CoAs. The reaction is a committed step in mitochondrial fatty acid beta-oxidation and is therefore central to energy homeostasis, especially in tissues with high oxidative demand such as heart and skeletal muscle. For researchers, GO:0016937 is important because it connects a single enzymatic reaction to systemic metabolic phenotypes. Genetic or pharmacological modulation of short-chain acyl-CoA dehydrogenase (SCAD) alters body weight, insulin sensitivity, and cardiac stress responses in model systems. In addition, SCAD has been proposed as a target in vascular remodelling, indicating that this activity influences cell types beyond classical metabolic tissues. Because the reaction is chemically well defined, GO:0016937 is also a useful benchmark for assay development. Native electrophoresis in-gel activity assays can resolve acyl-CoA dehydrogenase activities and reveal biological insights into dehydrogenase deficiencies. This makes the term a practical anchor for both mechanistic enzymology and translational studies.
short-chain fatty acyl-CoA dehydrogenase activity At A Glance
| GO ID | GO:0016937 |
|---|---|
| GO term | short-chain fatty acyl-CoA dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | butanoyl-CoA dehydrogenase; butyryl dehydrogenase; short-chain acyl CoA dehydrogenase; short-chain-acyl-CoA dehydrogenase activity; unsaturated acyl-CoA reductase |
| Major function | Oxidation of short-chain 2,3-saturated fatty acyl-CoA to short-chain (2E)-enoyl-CoA with reduction of electron-transfer flavoprotein |
| Substrate specificity | Short-chain fatty acyl-CoAs with aliphatic tails of fewer than 6 carbons |
| Electron acceptor | Electron-transfer flavoprotein (oxidized form) |
| Reaction direction | Forward direction supports fatty acid beta-oxidation; the reverse reaction is described as unsaturated acyl-CoA reductase activity |
| Representative enzyme | Short-chain acyl-CoA dehydrogenase (SCAD), encoded by ACADS in humans |
What Is GO:0016937?
In simple terms, GO:0016937 is the activity that strips hydrogen atoms from a short-chain fatty acyl-CoA molecule and passes the electrons to electron-transfer flavoprotein. The official definition states: Catalysis of the reaction: a short-chain 2,3-saturated fatty acyl-CoA + H+ + oxidized [electron-transfer flavoprotein] = a short-chain (2E)-enoyl-CoA + reduced [electron-transfer flavoprotein]. A short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons. Synonyms include butanoyl-CoA dehydrogenase, butyryl dehydrogenase, short-chain acyl CoA dehydrogenase, short-chain-acyl-CoA dehydrogenase activity, and unsaturated acyl-CoA reductase.
Why Is short-chain fatty acyl-CoA dehydrogenase activity Important in Cell Biology?
GO:0016937 matters because it defines the first oxidative step for short-chain fatty acyl-CoAs in mitochondrial beta-oxidation, a pathway that supplies reducing equivalents and acetyl-CoA for energy production. Dysregulation of this activity has been associated with altered body weight and insulin sensitivity in mice, with cardiac stress responses and cardiomyocyte apoptosis, and with vascular remodelling. Because the reaction is measurable and genetically tractable, it serves as a model for understanding how a single enzymatic activity can influence systemic metabolism and disease.
• Defines a rate-contributing step in mitochondrial beta-oxidation of short-chain fatty acids.
• SCAD deficiency protects mice against diet-induced obesity and insulin resistance, linking the activity to metabolic disease.
• SCAD modulates cardiomyocyte apoptosis, connecting the activity to cardiac cell survival.
• SCAD expression and activity change during rat cardiac development and under stress.
• SCAD is a potential target for treating vascular remodelling.
• The reaction transfers electrons to electron-transfer flavoprotein, coupling beta-oxidation to the respiratory chain.
• In-gel activity assays for acyl-CoA dehydrogenases provide diagnostic and mechanistic readouts for dehydrogenase deficiencies.
• Short-chain acyl-CoA metabolism intersects with branched-chain fatty acid synthesis in some bacteria, highlighting broader acyl-CoA biology.
• Autophagy regulation by acetylation can influence mitochondrial metabolism, providing crosstalk with this activity.
• Metabolic myopathies often involve defects in fatty acid oxidation enzymes, making this activity clinically relevant.
GO:0016937 short-chain fatty acyl-CoA dehydrogenase activity: Mechanism, Genes and Research Methods
Substrate recognition and binding
In simple terms: The enzyme must first grab the correct short-chain fatty acyl-CoA molecule.
Short-chain acyl-CoA dehydrogenase (SCAD) binds fatty acyl-CoA substrates whose aliphatic tails contain fewer than six carbons, as specified by the GO:0016937 definition. Substrate binding positions the acyl chain near the flavin cofactor so that the alpha and beta carbons can be oxidized. The specificity for short-chain substrates distinguishes this activity from medium- and long-chain acyl-CoA dehydrogenases, and native in-gel activity assays can resolve these different activities. In bacteria, short-chain acyl-CoA synthetases generate acyl-CoA substrates that feed into pathways such as branched-chain fatty acid synthesis, illustrating the broader metabolic context of short-chain acyl-CoA handling.
Dehydrogenation and electron transfer
In simple terms: The enzyme removes hydrogen from the fatty acid chain and sends the electrons to a carrier protein.
The catalytic step of GO:0016937 removes two hydrogens from the short-chain 2,3-saturated fatty acyl-CoA, forming a short-chain (2E)-enoyl-CoA. The electrons are transferred to oxidized electron-transfer flavoprotein, which becomes reduced. This coupling is essential because it links beta-oxidation to the mitochondrial electron transport chain. The reverse reaction is described by the synonym unsaturated acyl-CoA reductase, indicating that the enzyme can in principle catalyze reduction of the enoyl-CoA under appropriate conditions.
Role in mitochondrial beta-oxidation
In simple terms: This reaction is the first step in breaking down short-chain fats for energy.
GO:0016937 catalyzes the initial oxidation step for short-chain fatty acyl-CoAs in mitochondrial beta-oxidation. The product, a short-chain (2E)-enoyl-CoA, is subsequently hydrated and further oxidized to generate acetyl-CoA and reducing equivalents. Because short-chain fatty acids are handled by this dedicated activity, defects or changes in SCAD can shift the balance of lipid utilization. Metabolic myopathies often involve impaired fatty acid oxidation, and this activity is part of the enzymatic network relevant to those disorders.
Tissue-specific expression and stress responses
In simple terms: The amount and activity of this enzyme change depending on the tissue and stress conditions.
SCAD expression and activity change during rat cardiac development and in response to stress, indicating developmental and stress-dependent regulation of GO:0016937. In cardiomyocytes, SCAD influences apoptosis, so changes in this activity can affect cell survival under stress. In vascular remodelling, SCAD has been proposed as a potential target, suggesting that the activity also operates in vascular cells. These observations show that GO:0016937 is not a static housekeeping function but is dynamically regulated across tissues.
Metabolic and systemic consequences
In simple terms: Changing this enzyme activity can change whole-body metabolism.
Deficiency in short-chain acyl-CoA dehydrogenase protects mice against diet-induced obesity and insulin resistance, demonstrating that loss of GO:0016937 activity can have systemic metabolic benefits in a controlled experimental setting. This finding links the enzymatic reaction to energy balance and glucose homeostasis. Because autophagy regulation by acetylation can affect mitochondrial metabolism, there is potential crosstalk between acetylation-dependent pathways and short-chain acyl-CoA oxidation. Together, these studies position GO:0016937 as a node connecting mitochondrial fatty acid oxidation to organism-level metabolic phenotypes.
Key Genes Involved in GO:0016937 short-chain fatty acyl-CoA dehydrogenase activity
The following genes and proteins are directly or functionally associated with short-chain fatty acyl-CoA dehydrogenase activity (GO:0016937) and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACADS | Encodes short-chain acyl-CoA dehydrogenase, the enzyme catalyzing GO:0016937 | Core enzyme for substrate oxidation and electron transfer to electron-transfer flavoprotein |
| ETFA | Encodes the alpha subunit of electron-transfer flavoprotein | Accepts electrons from acyl-CoA dehydrogenases including SCAD |
| ETFB | Encodes the beta subunit of electron-transfer flavoprotein | Part of the electron acceptor complex for GO:0016937 |
| ETFDH | Encodes electron-transfer flavoprotein dehydrogenase | Links reduced electron-transfer flavoprotein to the respiratory chain |
| HADHA | Encodes the alpha subunit of mitochondrial trifunctional protein | Acts downstream in beta-oxidation after the dehydrogenase step |
| HADHB | Encodes the beta subunit of mitochondrial trifunctional protein | Supports subsequent steps of fatty acid oxidation |
| ACADM | Encodes medium-chain acyl-CoA dehydrogenase | Related acyl-CoA dehydrogenase with distinct chain-length specificity |
| ACADVL | Encodes very long-chain acyl-CoA dehydrogenase | Related enzyme for long-chain substrates, useful for comparative studies |
| CPT1A | Encodes carnitine palmitoyltransferase 1A | Controls entry of fatty acids into mitochondria upstream of beta-oxidation |
| CPT2 | Encodes carnitine palmitoyltransferase 2 | Involved in fatty acid transport for oxidation |
| SLC25A20 | Encodes carnitine-acylcarnitine translocase | Facilitates acyl-carnitine transport across the inner mitochondrial membrane |
| PPARA | Encodes peroxisome proliferator-activated receptor alpha | Regulates fatty acid oxidation gene expression, including ACADS |
| PPARGC1A | Encodes PGC-1alpha | Coactivator that promotes mitochondrial biogenesis and oxidative metabolism |
| SIRT1 | NAD-dependent deacetylase | Acetylation-dependent regulation can influence mitochondrial metabolism |
| SQSTM1 | Encodes p62, an autophagy receptor | Autophagy regulation intersects with mitochondrial metabolism |
| MAP1LC3B | Encodes LC3B, an autophagy marker | Used to monitor autophagy in metabolic studies |
| ATGL | Encodes adipose triglyceride lipase | Supplies fatty acids for beta-oxidation |
How Is short-chain fatty acyl-CoA dehydrogenase activity Regulated?
GO:0016937 activity is regulated at multiple levels. Expression of ACADS and other fatty acid oxidation genes is influenced by PPARA and PPARGC1A, which coordinate mitochondrial oxidative capacity. Acetylation-dependent pathways, including SIRT1 and autophagy-related proteins, can modulate mitochondrial metabolism and may indirectly affect short-chain acyl-CoA oxidation. In the heart, SCAD expression and activity change during development and under stress, indicating physiological regulation of this activity. In vascular remodelling, SCAD has been proposed as a target, suggesting that its activity can be modulated in disease contexts.
short-chain fatty acyl-CoA dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACADS | Metabolic myopathy and fatty acid oxidation defects | ACADS knockout or point-mutation cell lines and mouse models |
| ACADS | Diet-induced obesity and insulin resistance | ACADS-deficient mice on high-fat diet |
| ACADS | Cardiomyocyte apoptosis and cardiac stress | Cardiac-specific ACADS knockout or overexpression in rat/mouse cardiomyocytes |
| ACADS | Vascular remodelling | Vascular smooth muscle cell models with ACADS knockdown or overexpression |
| ETFA/ETFB/ETFDH | Electron-transfer flavoprotein pathway defects | Knockout cell lines for electron-transfer flavoprotein components |
Metabolic myopathies and fatty acid oxidation defects
Metabolic myopathies include disorders of fatty acid oxidation, and defects in enzymes such as short-chain acyl-CoA dehydrogenase can impair energy production in muscle. Because GO:0016937 catalyzes an early step in short-chain fatty acid oxidation, reduced activity could contribute to exercise intolerance and other metabolic symptoms. Diagnostic approaches such as in-gel activity assays can help resolve dehydrogenase deficiencies.
Obesity and insulin resistance
Deficiency in short-chain acyl-CoA dehydrogenase protects mice against diet-induced obesity and insulin resistance, indicating that loss of GO:0016937 activity can improve metabolic parameters in this model. This counterintuitive finding suggests that short-chain acyl-CoA oxidation influences systemic energy balance and glucose handling. The result has implications for understanding how mitochondrial fatty acid oxidation contributes to metabolic disease.
Cardiac stress and apoptosis
SCAD expression and activity change during rat cardiac development and stress, and SCAD modulates cardiomyocyte apoptosis. These findings link GO:0016937 to cardiac cell survival and stress responses. Altered short-chain fatty acid oxidation may therefore affect heart function under pathological conditions.
Vascular remodelling
Short-chain acyl-CoA dehydrogenase has been proposed as a potential target for the treatment of vascular remodelling. This suggests that GO:0016937 activity participates in vascular smooth muscle or endothelial responses to injury. Targeting this activity could influence the structural changes of blood vessels in disease.
From short-chain fatty acyl-CoA dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the catalytic efficiency of SCAD for short-chain acyl-CoAs? | Purified recombinant ACADS with enzyme kinetics and in-gel activity assays |
| Does loss of SCAD protect against obesity? | ACADS knockout mouse fed a high-fat diet |
| How does SCAD affect cardiomyocyte survival? | ACADS overexpression or knockdown in cardiomyocytes |
| Does SCAD expression change during cardiac development? | Developmental time-course in rat heart tissue |
| Can SCAD be targeted in vascular remodelling? | Vascular smooth muscle cell models with ACADS modulation |
| How does SCAD deficiency alter mitochondrial metabolism? | ACADS knockout cells with metabolic flux analysis |
How to Study the short-chain fatty acyl-CoA dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In-gel activity assay | Acyl-CoA dehydrogenase activity after native electrophoresis | Resolving dehydrogenase deficiencies and enzyme specificity |
| Enzyme kinetics | Catalytic rate and substrate affinity | Characterizing SCAD variants and inhibitors |
| Metabolic flux analysis | Fatty acid oxidation and energy production | Linking GO:0016937 to metabolic phenotypes |
| RNA sequencing | ACADS and fatty acid oxidation gene expression | Tissue-specific and stress-dependent regulation |
| Western blotting | SCAD protein levels | Validating expression changes |
| Immunofluorescence | Subcellular localization of SCAD | Mitochondrial localization studies |
| Apoptosis assays | Caspase activity and cell death | Cardiomyocyte survival after SCAD modulation |
| CRISPR knockout | Loss-of-function phenotypes | Causal testing of ACADS in cells and mice |
Enzyme activity assays
Direct measurement of GO:0016937 activity uses short-chain fatty acyl-CoA substrates and monitors reduction of electron-transfer flavoprotein or formation of enoyl-CoA. These assays can be performed on tissue lysates or purified enzyme. Native electrophoresis in-gel activity assays can resolve acyl-CoA dehydrogenase activities and reveal biological insights into dehydrogenase deficiencies.
Metabolic flux and substrate analysis
Metabolic flux analysis can measure how loss or gain of SCAD activity affects fatty acid oxidation and energy production. Such experiments help connect GO:0016937 to systemic phenotypes such as obesity and insulin resistance. Substrate and product levels can be quantified by mass spectrometry.
Expression and regulation studies
Quantitative PCR, western blotting, and RNA sequencing can measure ACADS expression across tissues and conditions. These methods reveal developmental and stress-dependent changes in SCAD levels. Acetylation and autophagy-related regulation can be probed with acetylation-specific antibodies and autophagy markers.
Genetic and pharmacological perturbation
Knockout, knockdown, and overexpression models allow causal testing of GO:0016937 in cells and animals. Pharmacological inhibitors or activators can complement genetic approaches. Phenotypic readouts include cell survival, lipid accumulation, and insulin sensitivity.
How CRISPR Can Be Used to Study GO:0016937 short-chain fatty acyl-CoA dehydrogenase activity
Knockout
CRISPR knockout of ACADS can eliminate short-chain fatty acyl-CoA dehydrogenase activity (GO:0016937) in cells or animal models. This approach has been used to show that SCAD deficiency protects mice against diet-induced obesity and insulin resistance. Knockout models are valuable for defining the metabolic consequences of losing this enzymatic activity.
Point Mutation
Point mutations in ACADS can be introduced to mimic naturally occurring variants or to dissect catalytic residues. Such models help determine which residues are required for substrate binding and electron transfer to electron-transfer flavoprotein. Point-mutation cell lines can be used to study genotype-phenotype relationships in fatty acid oxidation disorders.
Knock-in
Knock-in of tagged or reporter versions of ACADS allows tracking of SCAD expression and localization in vivo. Tagged knock-in models can be used to monitor developmental and stress-dependent changes in SCAD levels. These models also facilitate biochemical purification of the enzyme for activity assays.
Overexpression
Overexpression of ACADS can increase GO:0016937 activity in cells and tissues. This approach has been used to study effects on cardiomyocyte apoptosis and vascular remodelling. Overexpression models complement knockout studies by testing gain-of-function phenotypes.
How EDITGENE Supports short-chain fatty acyl-CoA dehydrogenase activity Research
Researchers studying short-chain fatty acyl-CoA dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic, cardiac, or vascular phenotypes. Building reliable CRISPR models is a critical step in that process.
Contact EDITGENE today to design your custom CRISPR model for short-chain fatty acyl-CoA dehydrogenase activity research.
Frequently Asked Questions About short-chain fatty acyl-CoA dehydrogenase activity
What is short-chain fatty acyl-CoA dehydrogenase activity?
It is the enzymatic activity defined by GO:0016937 that oxidizes a short-chain 2,3-saturated fatty acyl-CoA to a short-chain (2E)-enoyl-CoA while reducing electron-transfer flavoprotein.
What genes are involved in short-chain fatty acyl-CoA dehydrogenase activity?
ACADS encodes the core enzyme, while ETFA, ETFB, and ETFDH encode electron-transfer flavoprotein components that accept electrons from the reaction.
What is the GO ID for short-chain fatty acyl-CoA dehydrogenase activity?
The GO ID is GO:0016937.
Which substrates does GO:0016937 act on?
It acts on short-chain fatty acyl-CoAs with aliphatic tails of fewer than six carbons.
How is short-chain fatty acyl-CoA dehydrogenase activity measured?
It can be measured by enzyme activity assays and native in-gel activity assays that resolve acyl-CoA dehydrogenase activities.
What diseases are linked to short-chain acyl-CoA dehydrogenase?
It has been linked to metabolic myopathies, obesity and insulin resistance, cardiac stress and apoptosis, and vascular remodelling.
Does SCAD deficiency affect body weight?
Yes, deficiency in short-chain acyl-CoA dehydrogenase protects mice against diet-induced obesity and insulin resistance.
How does SCAD affect the heart?
SCAD expression and activity change during cardiac development and stress, and SCAD modulates cardiomyocyte apoptosis.
Can CRISPR be used to study GO:0016937?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to study ACADS and related genes.
What is the relationship between GO:0016937 and electron-transfer flavoprotein?
The reaction catalyzed by GO:0016937 reduces oxidized electron-transfer flavoprotein, coupling fatty acid oxidation to the respiratory chain.
Conclusion
GO:0016937, short-chain fatty acyl-CoA dehydrogenase activity, is a well-defined molecular function that catalyzes the oxidation of short-chain fatty acyl-CoAs and transfers electrons to electron-transfer flavoprotein. It is central to mitochondrial beta-oxidation and has been linked to metabolic, cardiac, and vascular phenotypes in model systems. Continued research using CRISPR-engineered models and activity assays will clarify how this activity contributes to health and disease.
References
- 1. Xu Y et al.. 2023. Acetylation in the regulation of autophagy.. Autophagy 19(2):379-387 PMID: 35435793
- 2. Whaley SG et al.. 2023. A short-chain acyl-CoA synthetase that supports branched-chain fatty acid synthesis in Staphylococcus aureus.. J Biol Chem 299(4):103036 PMID: 36806679
- 3. Zhong X et al.. 2023. Short-chain acyl-CoA dehydrogenase is a potential target for the treatment of vascular remodelling.. J Hypertens 41(5):775-793 PMID: 36883465
- 4. Tein I. 1996. Metabolic myopathies.. Semin Pediatr Neurol 3(2):59-98 PMID: 8795843
- 5. Guerrero-Castillo S et al.. 2025. High-resolution native electrophoresis in-gel activity assay reveals biological insights of medium-chain fatty acyl-CoA dehydrogenase deficiency.. Sci Rep 15(1):37168 PMID: 41131340
- 6. Chen Y et al.. 2019. Deficiency in the short-chain acyl-CoA dehydrogenase protects mice against diet-induced obesity and insulin resistance.. FASEB J 33(12):13722-13733 PMID: 31585505
- 7. Zeng Z et al.. 2016. Effects of short-chain acyl-CoA dehydrogenase on cardiomyocyte apoptosis.. J Cell Mol Med 20(7):1381-91 PMID: 26989860
- 8. Huang J et al.. 2015. Changes in short-chain acyl-coA dehydrogenase during rat cardiac development and stress.. J Cell Mol Med 19(7):1672-88 PMID: 25753319
